ABSTRACT Waning vaccine-induced immunity coupled with the emergence of SARS-CoV-2 variants has led to increases in breakthrough infections, prompting consideration for vaccine booster doses. Boosters have been reported to be safe and increase SARS-CoV-2-specific neutralizing antibody levels, but how these doses impact the trajectory of the global pandemic and herd immunity is unknown. Information on immunology, epidemiology, and equitable vaccine distribution should be considered when deciding the timing and eligibility for COVID-19 vaccine boosters.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Immunity, Vaccines, 【초록키워드】 neutralizing antibody, immunology, Vaccine, COVID-19 vaccine, Epidemiology, SARS-CoV-2 variant, global pandemic, SARS-CoV-2 variants, herd immunity, breakthrough infections, trajectory, distribution, dose, Vaccine-induced immunity, Safe, booster doses, Increases, eligibility, reported, increases in, the timing, 【제목키워드】 Science,
【저자키워드】 COVID-19, SARS-CoV-2, Immunity, Vaccines, 【초록키워드】 neutralizing antibody, immunology, Vaccine, COVID-19 vaccine, Epidemiology, SARS-CoV-2 variant, global pandemic, SARS-CoV-2 variants, herd immunity, breakthrough infections, trajectory, distribution, dose, Vaccine-induced immunity, Safe, booster doses, Increases, eligibility, reported, increases in, the timing, 【제목키워드】 Science,
요약 SARS-CoV-2 변이체의 출현과 결합된 백신 유도 면역 약화로 인해 돌발성 감염이 증가하여 백신 추가 용량에 대한 고려가 촉구되었습니다. 부스터는 안전하고 SARS-CoV-2-특이적 중화 항체 수준을 증가시키는 것으로 보고되었지만 이러한 용량이 세계적 대유행 및 집단 면역의 궤적에 어떻게 영향을 미치는지는 알려져 있지 않습니다. COVID-19 백신 부스터의 시기와 적격성을 결정할 때 면역학, 역학 및 공평한 백신 배포에 대한 정보를 고려해야 합니다.